Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Oudard, Stéphane; Banu, E.; Beuzeboc, Philippe; Voog, Éric; Dourthe, Louis Marie; Hardy-Bessard, Anne Claire; Linassier, Claude; Scotté, Florian; Banu, A.; Coscas, Yvan; Guinet, F; Poupon, Marie‐France; Andrieu, Jean‐Marie

doi:10.1200/jco.2005.12.187

Cited by 129 publications

(92 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The serum PSA was thought to be correlated with cancer emergence, progression and efficacy of treatment [14,15], and some scholars proclaimed that the 'PSA era' had begun. However, many studies have found that serum PSA as an end point was unstable and heterogeneous for evaluating prognoses [16][17][18]. To improve the value of prediction, kinetic parameters based on PSA were developed that could more precisely reflect biological characteristics [7,13,19,20].…”

Section: Discussionmentioning

confidence: 99%

Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

et al. 2009

View full text Add to dashboard Cite

We investigated the potential value of prostate-specific antigen half-life (PSAHL) and decreasing velocity (PSAVd) to predict progression-free survival (PFS) and overall survival (OS) in Chinese patients with prostate cancer. A total of 153 patients treated with hormonal therapy were included in the study. Of these, 78 patients progressed to hormonerefractory prostate cancer (HRPC) and 24 patients died by the end of follow-up. PSAHL was defined as the time during which prostate-specific antigen (PSA) concentration became half of the initial value during the first hormonal therapy. PSAVd reflected the decreasing velocity of PSA during the first hormonal therapy. PFS was defined as the interval from the beginning of hormonal therapy to HRPC. Cox proportional hazards regression analysis was used to evaluate whether PSAHL and PSAVd were significantly associated with PFS and OS. The median PSAHL and PSAVd were 0.50 months and 33.8 ng mL −1 per month. The median PFS and OS were 22.7 months (95% confidence interval [CI], 22.0-29.6 months) and 43.5 months (95% CI, 37.9-48.4 months), respectively. On univariate and multivariate analysis, long PSAHL (> 0.5 months), metastatic disease, high biopsy Gleason scores (≥ 8) and high nadir PSA (> 0.4 ng mL −1 ) were all found to be significantly associated with short PFS. Long PSAHL, high nadir PSA and short PSA doubling time (PSADT ≤ 2.0 months) were significantly associated with short OS. There were no significant relationships between PSAVd and either PFS or OS. Thus, PSAHL is a promising new independent predictor of survival. Patients with long PSAHL were identified as those at high risk for a relatively short PFS and OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Recently, the taxanes (paclitaxel or docetaxel) with other agents, such as EMP or predonisone have been used for hormone-resistant prostate cancer (HRPC) and have shown good response (2)(3)(4)(5). Paclitaxel, which is purified from Taxus brevifolia, stabilize microtubule and causes apoptosis (6).…”

Section: Introductionmentioning

confidence: 99%

The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In fact, besides vinorelbine, 22,23 several studies have combined a taxane with estramustine with encouraging results in terms of response rate and survival. [24][25][26][27] However, significant toxicity was again observed in all of these studies. The thrombotic complications have been a source of concern for many investigators and have resulted in prophylactic regimens being introduced into the trials, with the aim of mitigating this toxicity.…”

Section: Discussionmentioning

confidence: 85%

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Bernardi

Talamini

Zanetti

et al. 2004

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone-prednisone.

show abstract

Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Abstract: The results of this randomized phase II study showed significantly higher PSA decline < or = 50% and longer times to progression in HRPC patients receiving DEP-based chemotherapy than MP, and that DEP could be proposed in this setting.

Cited by 129 publications

References 24 publications

Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines

Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial

Contact Info

Product

Resources

About